Hansa Biopharma AB (publ) (HNSA.ST)
HNSA.ST Stock Price Chart
Explore Hansa Biopharma AB (publ) interactive price chart. Choose custom timeframes to analyze HNSA.ST price movements and trends.
HNSA.ST Company Profile
Discover essential business fundamentals and corporate details for Hansa Biopharma AB (publ) (HNSA.ST) to support your stock research and investment decisions.
Sector
Healthcare
Industry
Biotechnology
IPO Date
17 Oct 2007
Employees
138.00
Website
https://www.hansabiopharma.comCEO
Renee Aguiar-Lucander
Description
Hansa Biopharma AB (publ), a biopharmaceutical company, develops immunomodulatory treatments for enabling transplants and rare immunoglobulin G (IgG)-mediated autoimmune conditions, gene therapy, and cancer using its proprietary enzyme technology platform. The company's lead drug candidate is Imlifidase, an antibody cleaving enzyme therapy that is in phase 3 clinical trial for use in sensitized kidney transplantations patients, as well as for anti-GBM antibody disease; and phase 2 clinical trial for antibody-mediated kidney transplant rejection and Guillain Barré syndrome. It is also developing Novel immunoglobulin cleaving enzymes for Repeat dosing (NiceR) for the treatment of autoimmune diseases, transplantation, and oncology; and Enzyme based antibody Enhancement (EnzE), which is cancer immunotherapy. The company has a preclinical research collaboration agreement with argenx BV to evaluate the therapeutic potential of combining the two companies' IgG-modulating technologies. Hansa Biopharma AB (publ) was incorporated in 2007 and is headquartered in Lund, Sweden.
HNSA.ST Financial Timeline
Browse a chronological timeline of Hansa Biopharma AB (publ) corporate events including earnings releases, dividend announcements, and stock splits.
Upcoming earnings on 22 Apr 2026
Upcoming earnings on 4 Feb 2026
Upcoming earnings on 23 Oct 2025
Earnings released on 17 Jul 2025
EPS came in at -kr 2.53 falling short of the estimated -kr 1.68 by -50.39%, while revenue for the quarter reached kr 49.12M , missing expectations by -22.25%.
Earnings released on 24 Apr 2025
EPS came in at -kr 0.55 surpassing the estimated -kr 2.67 by +79.40%, while revenue for the quarter reached kr 66.35M , missing expectations by -5.82%.
Earnings released on 6 Feb 2025
EPS came in at -kr 4.08 falling short of the estimated -kr 1.84 by -121.74%, while revenue for the quarter reached kr 32.34M , missing expectations by -60.32%.
Earnings released on 17 Oct 2024
EPS came in at -kr 1.53 surpassing the estimated -kr 2.42 by +36.78%, while revenue for the quarter reached kr 48.66M , missing expectations by -10.23%.
Earnings released on 18 Jul 2024
EPS came in at -kr 3.30 falling short of the estimated -kr 2.78 by -18.71%, while revenue for the quarter reached kr 34.33M , missing expectations by -36.66%.
Earnings released on 18 Apr 2024
EPS came in at -kr 4.15 falling short of the estimated -kr 3.46 by -19.94%, while revenue for the quarter reached kr 55.98M , beating expectations by +11.32%.
Earnings released on 4 Mar 2024
EPS came in at -kr 2.36 surpassing the estimated -kr 3.77 by +37.40%, while revenue for the quarter reached kr 50.41M , beating expectations by +19.80%.
Earnings released on 26 Oct 2023
EPS came in at -kr 4.78 falling short of the estimated -kr 3.75 by -27.47%, while revenue for the quarter reached kr 22.84M , missing expectations by -49.16%.
Earnings released on 20 Jul 2023
EPS came in at -kr 4.79 falling short of the estimated -kr 3.71 by -29.11%, while revenue for the quarter reached kr 36.65M , beating expectations by +11.10%.
Earnings released on 20 Apr 2023
EPS came in at -kr 3.92 falling short of the estimated -kr 2.92 by -34.37%, while revenue for the quarter reached kr 24.19M , missing expectations by -26.69%.
Earnings released on 2 Feb 2023
EPS came in at -kr 3.22 surpassing the estimated -kr 4.14 by +22.15%, while revenue for the quarter reached kr 30.77M , missing expectations by -0.79%.
Earnings released on 30 Sept 2022
EPS came in at -kr 3.45 falling short of the estimated -kr 1.90 by -81.72%, while revenue for the quarter reached kr 67.08M , beating expectations by +127.71%.
Earnings released on 30 Jun 2022
EPS came in at -kr 3.82 falling short of the estimated -kr 1.88 by -103.87%, while revenue for the quarter reached kr 26.40M , beating expectations by +41.30%.
Earnings released on 21 Apr 2022
EPS came in at -kr 3.11 surpassing the estimated -kr 3.61 by +13.77%, while revenue for the quarter reached kr 30.28M , beating expectations by +91.92%.
Earnings released on 3 Feb 2022
EPS came in at -kr 3.67 falling short of the estimated -kr 1.89 by -94.90%, while revenue for the quarter reached kr 15.40M , beating expectations by +11.30%.
Earnings released on 21 Oct 2021
EPS came in at -kr 2.98 , while revenue for the quarter reached kr 4.54M .
Earnings released on 30 Sept 2021
EPS came in at -kr 3.34 , while revenue for the quarter reached kr 4.95M .
Earnings released on 31 Mar 2021
EPS came in at -kr 2.34 , while revenue for the quarter reached kr 9.00M .
Earnings released on 31 Dec 2020
EPS came in at -kr 2.38 , while revenue for the quarter reached kr 3.83M .
Earnings released on 30 Sept 2020
EPS came in at -kr 2.77 , while revenue for the quarter reached kr 762.00K .
HNSA.ST Stock Performance
Access detailed HNSA.ST performance analysis with candlestick charts, real‑time intraday data and historical financial metrics for comprehensive insights.
Explore Related Stocks
Compare companies within the same sector by viewing performance, key financials, and market trends. Select a symbol to access the full profile.